CARsgen announces completion of series A financing

CARsgen, a leader in the development of Chimeric Antigen Receptors T (CAR-T) cell immunotherapy to treat a variety of cancers, today announced the completion of a series A financing led by BVCF, a China-based healthcare private equity fund.

CARsgen is an immunotherapy company focused on the development of new therapeutics for liver, lung, stomach and brain cancers. In collaboration with Shanghai Cancer Institute and Shanghai Renji Hospital, the company plans to initiate clinical studies for its lead therapeutic KJgpc3-001. KJgpc3-001 takes T-cells extracted from the patient, genetically modifies them to express a chimeric antigen receptor (CAR) for glypican-3 (GPC3), and then returns to the body to attack the liver cancer. GPC3 is overexpressed in the majority of liver cancers (hepatocellular carcinoma (HCC), and in preclinical studies, KJgpc3-001 eradicated HCC cells.

"HCC is the fifth most common cancer and the third most common cause of cancer mortality worldwide," said Li Zonghai, M.D., Ph.D., CEO of CARsgen. "The vast majority of liver cancer patients live in China and unfortunately, it remains underdiagnosed and inadequately treated, with a very high rate of death within the first five years of diagnosis. CARsgen's game-changing CAR-T approach offers new hope for HCC patients. We are proud to complete this financing led by BVCF, a leading healthcare investor in China, and look forward to accelerating our work to bring revolutionary CAR-T cell therapy to HCC patients, and eventually to other cancer patients as well."

Dr. Zhi Yang, the managing partner of BVCF, "We are very excited to be involved in the evolution of CARsgen. The leadership team has a strong background in cancer biology, cancer immunology, and antibody development, as well as clinic cellular therapy technology and has assembled a strong proprietary position in CAR-T cell therapy specifically. Additionally, CARsgen has established a great working relationship with several prominent hospitals in Shanghai, including Renji Hospital, the first western medicine hospital in Shanghai.

Source:

CARsgen

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
First U.S. trial uses non-viral CRISPR to correct sickle cell mutation